[ad_1] The Phase 2/3 Emory Molecular Prostate Imaging for Radiotherapy Enhancement, or study EMPIRE-1 (NCT01666808), is the first randomized study in men with recurrent prostate cancer to demonstrate that advanced molecular imaging treatment can improve rates disease-free survival.1 The study, presented at the American Society for Radiation Oncology (ASTRO) annual …
Read More »The first phase 2/3 EMPIRE-1 study showed increased failure-free survival in recurrent prostate cancer
